Safety and Efficacy Study of High Dose Colistin

• Status: Unknown status
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Colistin is a rapidly acting bactericidal antimicrobial agent that possesses a post antibiotic effect against MDRO Gram-negative bacteria, such as as Pseudomonas aeruginosa, Acinetobacterbaumannii, and Klebsiella pneumonia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King Saud Medical City
• Treatments: Colistin

Criteria

• Inclusion Criteria:

1. Patient age more than or equal 18 years old.

2. Patient has clinical signs and symptoms of infection with suspected or proven infection due to Carbapenem resistant microorganism.

3. Patient was started with Empirical therapy of Colistin and positive MDRO within 5 days of empirical therapy.

• Exclusion Criteria:

1. Patient age less than 18 years.

2. Pregnant patient.

3. If received Colistin treatment for less than 72 hours.

4. Renal Replacement Therapy.